Clinical trials: Non Organic Psychosis
Psychotic Disorder, Schizophreniform Disorder
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
Weight gain associated with antipsychotic medication use is a major side effect that limits the tolerability of these drugs. This often significant weight gain adversely affects health, increasing risks for developing…
- Conditions
- Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00287352
- Testing
- Olanzapine, Amantadine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia, Psychotic Disorders
Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
This study intends to compare novel antipsychotics ziprasidone and olanzapine, to confirm the findings of an open study -where stable patients receiving olanzapine switched to ziprasidone- which showed maintenance of clinical…
- Trial name
- NCT00145444
- Testing
- olanzapine, ziprasidone
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 100 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Lewy Body Dementia Psychosis
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
- Trial name
- NCT07029581
- Testing
- ACP-204
- Where
- 62 sites in United States, Bulgaria and 4 more
- Volunteers
- 180 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Psychotic Episode
Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis
The First-Episode Psychosis (FPE) is a severe disorder that can include delusions, cognitive disorders and suicidal behavior. In the majority of cases (more than 80%) it evolves into schizophrenia.
- Trial name
- PRESTO (NCT05813457)
- Testing
- PRESTO Early Identification Program
- Where
- 6 sites in France
- Volunteers
- 416 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Engagement, Patient, First Episode Psychosis
Optimizing Engagement in Services for First-Episode Psychosis
This study will compare a 12-session behavioral activation (BA) intervention modified for first-episode psychosis (FEP) to usual community mental health care (i.e., treatment-as-usual; TAU) delivered over 6 months with a sample…
- Trial name
- NCT05310838
- Testing
- Behavioral Activation for First Episode Psychosis, Treatment As Usual
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- California State University, San Bernardino
Mental Illness, Schizophrenia
Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use
Severe mental illness (SMI) refers to the most burdensome psychiatric conditions. The need to pre-empt the onset of SMI is pressing because once SMI develops, quality of life is poor and available treatments have limited…
- Conditions
- Mental Illness, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- IMAGINE (NCT03601026)
- Testing
- Genetic counselling
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Nova Scotia Health Authority
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Cognition, Healthy Participants
Cognitive Strategies in Early Psychosis 1
The goal of this clinical is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. The investigators will ask people who do not have psychosis to take a single dose of modafinil and then…
- Trial name
- COSTEP 1 (NCT07231497)
- Testing
- Modafinil
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia, Psychosis
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
- Conditions
- Schizophrenia, Psychosis, Metabolic Syndrome
- Trial name
- NCT03481465
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.
The aim of the present study is to evaluate the effectiveness of the addition of the postbiotic Pediococcus acidilactici (pA1c®HI) on amelioration of metabolic disturbances in patients with (FEP) or (SSD) treated with…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities, Postbiotic Supplement
- Trial name
- GLUCOPSICO (NCT07371325)
- Testing
- Pediococcus acidilactici, pA1c®HI postbiotic supplementation taking participants, Atypical antipsychotics (AAP)
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Manuel Jesús Cuesta Zurita
Premature Infant, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)
Preventing Vulnerable Child Syndrome in the NICU With Cognitive Behavioral Therapy (PreVNT Trial)
This study is being done to see if outcomes for both a premature infant's parents and the infant born prematurely who have spent time in the neonatal intensive care unit (NICU) can be improved through parent cognitive behavioral…
- Conditions
- Premature Infant, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Development, Child, Parent-Child Relations
- Trial name
- PreVNT (NCT03906435)
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia and Schizophrenia Spectrum Psychosis
Feeling Safe Study
The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms.
- Trial name
- NCT07234708
- Testing
- Sentirnos Seguros
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Schizophrenia, Schizoaffective Disorder
Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia
Many individuals with schizophrenia continue to hear voices, have false beliefs, and problems with attention, memory planning and everyday functioning even with medication treatment.
- Trial name
- Mcog (NCT01915017)
- Testing
- Cognitive Behavior Therapy for Psychosis, Cognitive Adaptation Training, Multi-modal Cognitive Therapy
- Volunteers
- 178 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
First Episode Psychosis
First Episode Psychosis and Pathway to Care in Nordland
First episode psychosis patients often experiences treatment delay. This reduces their prospects for recovery and makes unnecessary burdens for them and their carers.
- Trial name
- NCT01753284
- Volunteers
- 40 people
- Sponsor
- Nordlandssykehuset HF
Schizophrenia, Psychotic Disorders
Problem-solving-based Bibliotherapy Program for Family Caregivers
This proposed randomized controlled trial will test the effectiveness of a problem-solving based bibliotherapy program (PSBBP) for Chinese family caregivers in psychotic disorders (not more than 5 years onset).
- Trial name
- PSBBP (NCT02391649)
- Testing
- Self-learning program, Psycho-education program (in Phase 2)
- Where
- 2 sites in Hong Kong
- Volunteers
- 422 people
- Sponsor
- Chinese University of Hong Kong
Dissociative Disorders
Psychopathology of Dissociative Disorders
The goal of the project is to investigate the prevalence of dissociative disorders in psychiatric inpatients in Taiwan. Relevant clinical issues, including common psychiatric comorbidity (e.g., positive psychotic symptoms)…
- Trial name
- NCT01388140
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Psychoses
Brain Cell Injury in Patients With A First Episode of Psychosis
Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences…
- Trial name
- NCT00070889
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Alzheimer's Disease
CATIE-Alzheimer's Disease Trial
The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or…
- Trial name
- NCT00015548
- Testing
- Olanzapine, Quetiapine, Risperidone
- Where
- 34 sites in United States
- Volunteers
- 450 people
- Sponsor
- National Institute of Mental Health (NIMH)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.